Differential activity and clinical utility of latanoprost in glaucoma and ocular hypertension by Pacella, Fernanda et al.
© 2012 Pacella et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Clinical Ophthalmology 2012:6 811–815
Clinical Ophthalmology
Differential activity and clinical utility of latanoprost 
in glaucoma and ocular hypertension
Fernanda Pacella
Paolo Turchetti
Valentina Santamaria
David Impallara
Gianpaolo Smaldone
Chiara Brillante
Aloisa Librando
Angela Damiano
Jose Pecori-Giraldi
Elena Pacella
Department of Sense Organs, 
University of Rome “Sapienza”, 
Roma, Italy
Correspondence: Fernanda Pacella 
Department of Sense Organs, Viale del 
Policlinico, Rome 00161, Italy 
Tel +39 06 49975305 
Fax +39 06 49975304 
Email pacella.ferny@libero.it
Background: The purpose of this study was to demonstrate the hypotensive efficacy and   tolerability 
of latanoprost when used as monotherapy and as polytherapy associated with   antiglaucomatous 
medication proven to be ineffective in keeping intraocular pressure under control.
Methods: Three hundred and thirty-seven patients (672 eyes) affected by primary open-angle 
glaucoma and intraocular hypertension were recruited over a period of 10 years from the 
  Glaucoma Centre, Department of Ophthalmological Sciences, University of Rome “Sapienza”, 
and treated, subject to informed consent, with latanoprost 0.005% alone or in combination 
with other ocular hypotensive drugs. The patients were followed during this period at regular 
intervals, with determination of visual field, fundus oculi, visual acuity, and eventual onset of 
local and systemic side effects.
Results: Latanoprost used as monotherapy and as polytherapy renders possible optimal and 
durable control of intraocular pressure in the form of one antiglaucomatous drug because it can 
substitute for one or more drugs and obtain the same hypotensive effect.
Conclusion: Latanoprost can be described as the ideal hypotensive drug, not only because of 
its ideal compliance profile (only one daily dose in the evening), excellent hypotensive effect, 
and, above all, few systemic side effects.
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Introduction
Analogs of prostaglandins (such as latanoprost, a prodrug of prostaglandin F2α) have 
been used as antiglaucomatous therapy since 1995.1 Prostaglandins are eicosanoids 
belonging to the family of autacoids, and constitute a group of molecules with ubiq-
uitous distribution that performs various physiological functions in many organs and 
tissues, and vary according to type of prostaglandin and the receptor upon which it 
acts. For example, at the ocular level, prostaglandins induce miosis (albeit not in all 
animal species), vasomotor hyperemia, and disruption of the hemato-ophthalmic 
barrier, causing increased capillary protein permeability and increased intraocular 
pressure. While the action on EP2 receptors induces an increment in pressure at the 
ocular level, the opposite effect is obtained with the action of prostaglandin F2α on the 
prostanoid FP receptor. Latanoprost is an inactive esterified prodrug of the isopropyl 
group that becomes biologically active following hydrolysis in the acid form. The 
prodrug, well absorbed through the cornea, is hydrolyzed and then activated during 
its passage across the aqueous humor.
From 1980 until the present day, several derivatives of prostaglandin F2α have been 
tested,2–5 including prostaglandin F2α-isopropyl ester (IE), PHXA34   (13,14-dihydro-15 
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(R,S)-17 fenil-18,19,20-trinor-prostaglandin-IE) epimeter 
of PHXA41 (13,14 dihydro, 15 (5), 17 fenil, 18, 19, 20 trinor 
prostaglandin F2α-IE), from which latanoprost (Xalatan®) 
is derived and shown to have the widest clinical application. 
After various studies carried out in animals, human experi-
ments were performed in order to evaluate the hypotensive 
effect in subjects with glaucoma. While prostaglandins 
E2 and D2 increased intraocular pressure, prostaglandin 
F2 (in the form of the tromethamine salt of prostaglandin 
F2α applied locally), although having notable side effects, 
decreased intraocular pressure in the order of 3–4 mmHg. 
These effects could be reduced by inserting into position 1 an 
external isopropyl which was more liposoluble   (prostaglandin 
F2α-IE), thus allowing a smaller dose to be administered, 
which was activated by corneal esterase.
Prostaglandin F2α-IE is a potent ocular hypotensive agent 
with no effect on production of aqueous humor or on conven-
tional outflow. Doses inferior to those on the dose-response 
curve are considered suitable for clinical use, whereas high 
doses produce numerous side effects, in part mitigated by 
reducing the use of the 1,15 diester.
A considerable reduction in intraocular pressure (by 25%) 
and side effects1–3,6 is obtained by positioning a phenolic 
group (PhXA34) in position 17, obtaining a racemic product 
(PHXA41), resulting in an extremely effective R-epimer 
form, which at the same time permits dose reduction.
The mechanism of action by which latanoprost reduces 
intraocular pressure is based on facilitating uveoscleral 
outflow. Uveoscleral passage starts at the base of the iris 
and passes through the ciliary muscle in the over ciliary 
space and then into the superchoroidal space.7 The action 
of a prostaglandin on the ciliary muscle occurs in a manner 
related to the length of the stimulus. The first short-term 
effect that manifests itself is relaxation of the ciliary muscle 
induced by receptors specific for prostaglandins present in 
the muscle itself. In contrast, the long-term effect depends 
on readaptation induced in the extracellular matrix adjacent 
to the fibers of the ciliary muscle, with loss of connective 
tissue and subsequent facilitation of uveoscleral outflow 
through the muscle fibers.
Recent studies have clarified the distribution of the main 
prostaglandin receptors affecting intraocular pressure in 
the human eye, ie, prostaglandin E1, prostaglandin E2, and 
prostaglandin F2α. EP1 receptors have been identified in the 
ciliary body and the sphincter of the iris, EP3 receptors are 
found in the trabecular meshwork and ciliary muscle, and FP 
receptors (mainly acted upon by prostaglandins) are exclu-
sively localized in the ciliary muscle. This latter   phenomenon 
would explain the selective actions of   prostaglandin F2α and 
latanoprost on uveoscleral outflow. It is important to empha-
size that the hypotensive effects of prostaglandin F2α and 
latanoprost are due to the action of very low doses of these 
substances which act selectively on FP receptors. The aim 
of this study was to demonstrate the hypotensive activity 
and good tolerability of latanoprost, both as monotherapy 
and when used to replace antiglaucomatous medications 
which have proven to be ineffective in keeping intraocular 
pressure under control.
Materials and methods
Preliminary study
Two groups of patients were recruited to participate in 
a randomized multicenter, double-blind study in which 
one group of patients received latanoprost 0.005% once 
a day and the other group received timolol 0.5% twice 
a day for 6 months.8 Seventy-one patients with primary 
open-angle glaucoma were selected. Their mean age was 
63.3 ± 10.5 years, they comprised 35 females and 36 males. 
Both groups were then followed for a further 18 months with 
latanoprost administered as a single daily dose.
Long-term study
Over a period of 10 years, 266 patients affected by primary 
open-angle glaucoma and ocular hypertension were treated, 
having given their informed consent. Of these, 132 were 
males of average age 61.39 ± 14 years, and 134 were females 
of average age 64.20 ± 13.55 years, for a total of 530 eyes 
(two cases were monocular). During the first visit, all patients 
underwent the following examinations: biomicroscopy of the 
anterior segment; visual acuity; intraocular pressure; ocular 
fundus; manual and computerized perimetry; gonioscopy; 
and daily tonometric curve. When the diagnosis of primary 
open-angle glaucoma and ocular hypertension had been 
confirmed, treatment was initiated with latanoprost at a 
concentration of 0.005% in monotherapy or in association 
with other antiglaucomatous drugs.
At regular time intervals, intraocular pressure (every 
2–3 months), perimetry (every 10–12 months) and annual 
examination of the ocular fundus and visual acuity were 
carried out, taking the eventual onset of local and systemic 
collateral effects into consideration. We excluded eyes 
that presented with anomalies in the corneal profile (eg, 
keratoconus) and alterations of the corneal epithelium 
(inflammatory and/or degenerative processes), and wearers 
of soft contact lenses. Patients were included in the study if 
they had had latanoprost substituted for one of their drugs, 
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if latanoprost had been added to conventional therapy, 
and if dual therapy had been substituted by latanoprost as 
monotherapy. Statistical analysis was performed using the 
Student’s t-test. P = 0.01 was considered to be statistically 
significant.
Results
Preliminary study
It was demonstrated that latanoprost administered once 
daily and timolol 0.5% twice daily were able to significantly 
(P , 0.001) reduce mean intraocular pressure by a mean 
8 mmHg. Figure 1 illustrates the mean course of intraocular 
pressure in both eyes at various time intervals (months 0, 1, 
2, 3, 6) following the administration of latanoprost once daily 
and timolol 0.5% twice daily. Of interest is that even after 
only one month of treatment with latanoprost, there was an 
average reduction of intraocular pressure of 23.15% which 
remained constant during the entire 12-month period of 
observation. Table 1 shows a statistical analysis of intraocular 
pressure values obtained before and 12 months after the start 
of latanoprost once daily.
Long-term study
Drugs which were substituted by latanoprost to achieve an 
increase in hypotensive activity are described in Table 2. 
It may be seen that the drugs more frequently substituted 
were parasympathomimetics (14.33%), anhydrase   inhibitors 
(10.94%), and beta-blockers (8.67%). Table 3 shows the 
association of latanoprost and other ocular hypotensive drugs 
with different mechanisms of action which proved ineffective 
in reducing intraocular pressure.
These studies demonstrate that latanoprost can be 
  particularly useful in the medical treatment of some forms 
of glaucoma, such as normotensive glaucoma, where the 
  damage cannot be specifically attributed to a steady increment 
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Figure 1 Mean intraocular pressure values before and after administration of latanoprost once daily and timolol 0.5% twice daily.
in intraocular pressure. Other studies1,6,9,10 have demonstrated 
that latanoprost at concentrations of 0.005% administered 
once daily achieves an average intraocular pressure   reduction 
of 35% in patients with primary open-angle glaucoma and 
ocular hypertension.
Given the fact that latanoprost increases uveoscleral 
outflow, it can be used as adjunctive therapy with other 
drugs having different hypotensive ocular activity, such as 
beta-blockers, carbonic anhydrase inhibitors administered 
both systemically and locally, alpha stimulants, and cholin-
ergic drugs.
In order to demonstrate the effectiveness of latanoprost 
as monotherapy compared with maximum antiglaucomatous 
therapy that proved insufficient in keeping intraocular pres-
sure under control in patients affected by primary open-angle 
glaucoma, we proceeded with evening administration in 
addition to a combination of antiglaucomatous drugs, the 
latter having demonstrated their ineffectiveness in keeping 
intraocular pressure under control. Assessments at months 1, 
2, 3, 6, and 9 following addition of latanoprost consistently 
showed a statistically significant (P = 0.001) reduction in 
intraocular pressure compared with baseline values.
During a decade of experience with latanoprost, we 
noted local collateral effects, consisting of   dysepithelization 
(1.13%), dryness of the periocular skin (0.37%),   ocular 
Table 1 Statistical analysis of intraocular pressure values prior to 
and after latanoprost instillation
Time  
months
Eyes (n) Intraocular pressure P
Median ± MSE t
0  35 23.20 ± 0.53 – –
3  35 16.97 ± 0.49 8.631 0.001
6  35 17.11 ± 0.38 9.338 0.001
9  35 17.71 ± 0.43 8.044 0.001
12  35 17.89 ± 0.45 7.637 0.001
Abbreviation: MSE, mean standard error.
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dryness (0.70%), ocular pain (1.13%), peripalpebral 
edema (3.52%), and lacrimation (2.81%). Evidence of 
cystoid macular edema, described by some authors, was 
very rare in our experience during treatment of aphakic or 
  pseudoaphakic eyes. However, according to the literature, 
such   manifestations cannot be confidently attributed to 
the drug because they have never been documented during 
  clinical trials. Other topical side effects observed were: edema 
of  the lacrimal caruncle (0.70%), keratitis (1.40%), growth 
of the cilium (7.04%), and irideal hyperpigmentation (2.81%, 
the latter phenomenon starts concentrically at the pupil edge 
and does not recede after interruption of the therapy; this is 
due to stimulation by the drug of melanogenesis in the iris 
stroma3,5). This is due to stimulation by the drug of melano-
genesis in the iris stroma.3,5
The drug was well tolerated locally, with the exception 
of one eye in one patient who, after 3 months, developed 
a keratopathy comprising corneal disepithelization with 
parenchymal infiltration in the left eye, and treatment was 
suspended for this reason. However, when only one eye is 
involved, it is difficult to establish cause and effect due to 
latanoprost. Regarding systemic collateral effects associated 
with administration of latanoprost, the following were found: 
headache (2.11%), vertigo (1.40%), dry fauces (0.70%), 
dermatitis (0,70%), and gastroesophageal reflux (0.18%). 
The latter receded as soon as latanoprost was interrupted, and 
then reappeared within one month of restarting the drug.
Discussion
Numerous antihypertensive pharmacological therapies 
can be used in patients affected by glaucoma and   ocular 
  hypertension, and there is no single drug that can be 
  considered to be the best choice for a given patient. The six 
classes of drugs (miotics, beta-blockers, alpha-agonists, 
adrenalin derivatives, carbonic anhydrase inhibitors, pros-
taglandin analogs) and their combinations offer more than 
20 different medication options.
Pharmacokinetics of drugs administered locally involve 
interaction with the lacrimal film, intraocular factors, and 
  corneal penetration; each of these steps can be influenced by 
the vehicle, pH, from drug concentration, and the   preservatives 
used. Upon penetration into the cornea, the drugs have to 
cross the aqueous humor to reach the structures on which 
they act in the anterior segment of the eye. Some of the 
drug is eliminated via diffusion into the vascular system 
or leakage with the aqueous humor across the outflow 
system, while the remainder is delivered to the various 
ocular tissues.
It appears that latanoprost is efficacious with a durable 
hypotensive effect when used as monotherapy and also 
demonstrates good pharmacological synergism when used 
in association with other drugs that have not demonstrated 
efficacy in keeping intraocular pressure under control. 
  Moreover, latanoprost is effective when substituted for one or 
two drugs used in association, and manifests the same ocular 
hypotensive effect. Furthermore, latanoprost enables better 
compliance as a result of needing administration only once 
daily in the evening, compared with other antiglaucomatous 
drugs that usually require two or more administrations daily.1,6 
Finally, the drug is well tolerated in terms of the local and 
systemic side effects.
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